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Abstract  
Ethical guidance for genomic research is increasingly sought and perceived to be necessary. Although 
there are pressing ethical issues in genomic research – concerning for example the recruitment of 
patients/participants; the process of taking consent; data sharing; and returning results to 
patients/participants – there is still limited useful guidance available for researchers/clinicians or for 
the research ethics committees who review such projects.  
This report outlines the ethical principles and guidance for genomic research co-produced with 
stakeholders during two workshops which took place in the UK between November 2016 and May 
2017. The stakeholders involved in these workshops included: healthcare professionals, genomic 
research teams, academics, patients, biobank managers, and representatives from the Health Research 
Authority (HRA), NHS Research Ethics Committees, patient support groups, pharmaceutical industry, 
and health policy think tanks. The co-produced principles and guidance are specifically aimed at 
researchers/clinicians and members of NHS Research Ethics Committees, and are formulated with the 







Ethical guidance for genomic research is needed to improve research processes, to facilitate the 
translation of research in clinical practice, and to foster trust (and trustworthiness) amongst 
patients/participants and researchers, and other stakeholders. Whilst there is ethical guidance on 
clinical trials and broad research practice 1-4, there is scant relevant guidance available for 
researchers/clinicians undertaking genomic research, or for the research ethics committees who 
review projects 5.  
Therefore, such guidance is increasingly sought and perceived to be necessary. There are pressing 
ethical issues in genomic research concerning in particular: the recruitment of patients/participants; 
the process of taking consent; data sharing; and returning results to patients/participants. These issues 
are creating serious challenges to researchers, patients/participants, research ethics committee 
members, and other groups involved in genomic research.  For example, genomic research 
increasingly involves recruiting patients receiving health care to research, thus blurring lines between 
research and clinical practice. Feeding back individual findings to research participants, who are also 
often patients, may raise particular issues for participants concerning ongoing and future treatment 
decisions.   
One of the main benefits of the ethical debate in genomic research is to promote constructive 
interactions among research stakeholders. Ethics can inform the design and regulation of genomic 
research by helping to identify and to protect the needs of the diverse stakeholders. It is also important 
to note that current debates on the ethics of genomic research tend to exclude from meaningful 
engagement important stakeholders: the pharmaceutical industry, and other industry partners such as 
Contract Research Organisations (CRO).   
We have conducted three workshops with the objective of bringing together key stakeholders to 
reflect on the ethics of genomic research. The stakeholders involved in these workshops included: 
healthcare professionals (n=4), genomic research teams (n=5), academics (n=5), patients (n=2), 
patient support groups (n=1), biobank managers (n=2), and representatives from the Health Research 
Authority (HRA) (n=1), NHS Research Ethics Committees (n=1), pharmaceutical industry (n=2), and 
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health policy think tanks (n=1).  One of the patients participating in this workshop was involved in 
genomic research. Some, but not all the representatives from the above groups participated in all three 
workshops. This reflected our commitment to strike the balance between continuity of engagement 
and an inclusive participatory agenda.  
The aim of the first workshop was to identify important ethical issues, areas of best practices, general 
principles, and practical guidance 6. Building on these themes, the two subsequent workshops were 
organised to co-produce ethical principles and guidance specifically aimed at researchers/clinicians 
and NHS Research Ethics Committees (REC) members, with the understanding that these principles 
would also be relevant and accessible to other stakeholders involved in genomic research. Consensus 
on the principles and guidance was reached in the following way:  
During the second workshop we identified best ethical practice/approaches, and agreed upon general 
principles. These principles were subsequently shared with the participants via email, and additional 
feedback was incorporated.  
The aim of the third workshop was to further refine these principles and guidance. After the third 
workshop we shared the refined principles with the participants again, until we reached the version in 
this paper.   
To facilitate such interdisciplinary and ‘participatory’ discussions, we used in both the second and 
third workshops real cases and challenges encountered by the researchers/clinicians co-authors (CB, 
JM, TA) (see Supplementary material).  
 
This paper reports the outcomes of the last two workshops.  It outlines the ethical principles for 
genomic research agreed by the participants, followed by some specific considerations about the main 
challenges concerning informed consent, and suggestions about how these could be addressed. 
Particular attention has been given by the participants to the clarity and accessibility of the principles, 




Ethical Guiding Principles for Genomic Research  
 
Foundational requirement: appropriate training for research teams and NHS REC 
members is needed 
Structured eEfforts are needed to create or improve the training and resources available to support 
the design and ethical approval of genomic research studies. Training for both researchers (in 
particular those who are taking consent) and NHS REC members (who review research protocols) 
should be consistent and aligned. It should include information, resources, and, where possible, points 
of contact for REC members and researchers requiring specific scientific and ethical guidance (e.g. a 
bank of Scientific Officers as described in the Department of Health’s ‘Report 
of the Ad Hoc Advisory Group on the Operation of NHS Research Ethics Committees’7). 
 
1. Balancing the variety of research with ethical requirements   
There are different types of genomic research (understood as research on a complete set of DNA 
and /or its genes using biotechnological techniques). For example, there are exploratory projects (e.g. 
projects that look across populations rather than being focused on one disease), disease specific 
projects (e.g. studies to find the genetic causes of Inflammatory Bowel Disease), or gene-drug 
interaction projects. In addition, such projects employ different levels of genetic analysis e.g. 
candidate gene analysis, Genome Wide Association Studies, whole genome sequencing, RNA arrays.  
The objectives, nature, and obligations related to such different projects are likely to be diverse. 
Therefore, while it is important to follow legal and regulatory requirements, a one-size-fits-all policy 
to project design and ethics approval is unlikely to be the bestnot a good approach. A balance among  
the variety of research and ethical requirements  needs to be found as this can have an impact on all of 
the below principles listed below.  
 
2. Appropriate information at the appropriate time 
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Researchers should give patients/participants a suitable level of information about the research 
project 1at the right time. This information given also needs to be sufficient tomeet the requirements 
for compliancey with relevant data protection laws – but , but the question of legal compliance is 
outside the scope of this paper.  
What is suitable depends on characteristics of the potential participants: Are they vulnerable? Are 
they highly educated? Are they already research participants? Do they belong to an underserved 
group? In other words, suitability is influenced by different levels of vulnerability and the potential 
for emotional pressure (e.g. participants can include healthy volunteers or patients with a serious 
health condition looking for a diagnosis/treatment).  Patients/participants have different needs 
concerning the amount of information they wish to know about a project, and at what time.   
Information given to potential study patients/participants might be best provided in the form of a 
research ‘mission statement’. A research ‘mission statement’ should cover the main aim(s) of the 
research project; risk and benefits for patients/participants; commercial involvement; and a policy 
about returning results (see also §4). The research mission statement should be written in plain 
English, and be short, clear, and transparent. 
An information resource centre should be made available for patients/participants who wish to 
know further or additional information than that provided at the initial point of consent taking. This 
will include further information about the project design, what will happen to the participant/patient 
data, contact details of the research team (e.g. the type of information generated as part of the NHS 
Research Ethics applications), and already existing institutional/educational information about 
genomic research (e.g. educational animations produced by Genomics England). The idea is that the 
participants/patients will be able to access further information that will answer any questions they 
may have, when and how they choose.  This approach is in line with existing work such as: the HRA 
guidance on Proportionate Consent 1; the Trust-based approach to consent developed by the European 
School of Molecular Medicine and the European Institute of Oncology 8-10; Prainsack and Buyx’s 
approach to solidaristic data governance11 and the Global Genetic Alliance consent policy 12. It 
                                                          
1 This information given also needs to meet the requirements for compliance with relevant data protection laws 
– but the question of legal compliance is outside the scope of this paper. 
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ensures that individual patient needs and values are at the centre of genomic research, and that the 
recruitment and consent process is more patient focused, and more efficient for research teams.  
3. Research objectives and methods  
It is important to recognise the difference between the objectives of a research project (what are the 
questions that the research aims to address) and the methodology and technology adopted (how 
researchers plan to answer the research questions). This distinction has important implications for the 
generation of the project mission statement, the design of the research project, the research ethics 
approval process, and the development of any information given to participants/patients. Any 
materials made for the patient/participant, should be broad enough to keep up with any future changes 
to the research. This would ensure that only changes to the research mission statement would require 
ethical review and re-consenting by the participant/patients.  Patients/participants generally  
understand that research methods and technologies used evolve quickly, they also expect 
researchers to use the latest most powerful tools to answer their research questions 13.    
4. Policy about reporting results (broad, individual, and additional)  
Research teams should make an informed decision at the planning stage of a project about the 
strategy to adopt to report results. There should be a clear policy about what type(s) of results may 
be reported, by whom, how, and when, and how decisions on these aspects are made. The plan needs 
to be clearly outlined in the research mission statement and tailored to the specific type of genomic 
research (see §1, 2). 
Results which that may be reported to participants may fall into three major categories: broad 
general results (the main research outputs e.g. publications); individual level results (either 
uninterpreted or interpreted patient/participant data, should the individual samples have been tested) 
and additional findings (e.g. sought-for secondary findings or incidental findings). Some 
patients/participants, especially those seeking for a diagnosis, may also want to know whether their 
samples have been tested. 
Ethical and practical considerations should inform the decision about whether and how to report 
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research results.  For example, some long term projects may have systems to communicate with 
patients/participants which could be used to report research findings (e.g. a newsletter). Research that 
is very close to the clinical end of the spectrum may have these systems in place, especially where the 
research is conducted on patients who have an ongoing clinical relationship. Such situations will not 
only have an influence on the practicalities of whether the team might want to or find it easy to report 
back the results, but also potentially to what the participants/patients might expect.  
However, other projects may not have such systems and may not influence such expectations. 
Researchers should also consider that returning different types of results may have clinical and/or 
psychosocial implications for participants/patients who may require support (e.g. counselling). 
5. ‘Ethical’ Planning  
At the planning stage of a research project the potential questions, needs and risks to 
patients/participants should be considered. Researchers should also plan the most efficient, clear, and 
timely way to communicate with patients/participants and stakeholders through the life cycle of the 
project. This will depend on the type of project (see §1, 4), and may require training for both 
researchers and Research Ethics Committee members. Researchers should also consider the different 
educational background and understanding of genomic information of patients/participants 14. 
This ensures patient/participant focused research, builds trust and promotes transparency and 
reciprocity between researchers and patient/participants 15.  
 
6. Ethical guidance should enable participation  
Ethical regulations and guidance are there to support researchers to implement the above principles. 
They help researchers to identify and engage with stakeholders as part of the design of a project. 
Ethical regulation and guidance enable researchers to be more aware of how they (and their research) 
are situated within the broader community, the scientific environment, and the legal and 




Some notes on Informed consent  
Informed consent is needed, but we recognised that there are difficulties with current forms of 
consent 16: 
 The sheer quantity of information and the considerable number of forms to read/documents to 
sign may burden participants/patients and researchers – ultimately hindering research. 
Various types of information should be available for those participants who are interested in 
them; but not all available information may need to be given to participants at the time of 
recruitment (instead participants could be given guidance on how to access further 
information if required), in a layered fashion.   
 The complexity of the information conveyed to patients/participants – also due to the current 
need to balance different requirements from REC members, regulators, the law, etc. (clauses, 
adoption of particular types of form etc.). Consent serves different purposes for different 
stakeholders.  However, there is no need for patients/participants to know the specific laws 
and regulations that the consent is holding to. It is more important that the consent coveys to 
patients/participants the general principles that it is following (e.g., confidentiality) in an 
accessible fashion, in the form of a mission statement.  
 The lack of flexibility to patients/participants’ needs (see below) 
 
Best practice 
The Informed Consent document should: 
 Be seen as the basis for a conversation, as a process that engenders – and builds on – trust and 
trustworthiness, rather than a box ticking exercise that often serves the purpose to protect 
institutions rather than patients/participants     
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 Be short, easily comprehensible, and transparent. It should use simple language, supported by 
background information (an information resource centre). This could represent a starting 
point to promote genuine education and engagement and reduce knowledge and power 
imbalance amongst stakeholders 17. The adoption of such sources of background information 
may also reduce the time of the so-called ‘consent conversation’ for a specific research 
project between researcher and patients/participants.   
 Be flexible, exploring different modalities to convey the same information, and responding to 
the different ways in which patients/participants learn and look at information (e.g. video, 
media etc.). It should also be flexible in how it incorporates the requirements of regulators, 
law etc. 
 Not over-promise (e.g. promising to keep patients/participants’ identity entirely secure is 
inappropriate, as research has demonstrated that it is possible for anonymous data in genomic 
research to be re-identified 18.   
 
 
Researchers/Clinicians should:  
 Engage patients/participants in the process of developing the consent (and other 
patients/participants facing material), as early as possible in the design of research projects 
and certainly before applying to Research Ethics Committees.  Patient and Public 
Involvement groups – commonly composed of volunteers – are becoming more common 
across hospitals and research institutions 2 , and are playing an important role in ensuring that 
research is relevant to the needs of the public.  
o This would circumvent the phenomenon of ‘double- paternalism’: both researchers 
and committee’s members claiming to represent/protect the interest of 
patients/participants, or claiming to respond to what patients/participants are 
interested to know, without involving patients/participants  
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